title: Effects of sulfonylureas on tumor growth: a review of the literature.
abstract: Type 2 diabetes mellitus patients are at higher cancer risk, probably because of hyperinsulinemia and insulin growth factor 1 pathway activation. The effects of antidiabetic drugs on cancer risk have been described and discussed in several studies suggesting opposite effects of the biguanide metformin and sulfonylureas on cancer incidence and mortality. The anticancer mechanisms of metformin have been clarified, and some clinical studies, particularly in breast cancer patients, have been published or are currently ongoing; however, data about the effects of sulfonylureas on cancer growth are less consistent. The aims of this work are to review preclinical evidence of second-generation sulfonylureas effects on tumor growth, to clarify the potential mechanisms of action, and to identify possible metabolic targets for patient selection. Most evidence is on the adenosine triphosphate-sensitive potassium channels inhibitor glibenclamide, which interacts with reactive oxygen species production thus inducing cancer cell death. Among diarylsulfonylureas, next-generation DW2282 derivatives are particularly promising because of the proapoptotic activity in multidrug-resistant cells.
authors.affiliation: Second Medical Oncology Unit, Istituto Oncologico Veneto, Padua, Italy;
authors.forename: Giulia
authors.initials: G
authors.lastname: Pasello
authors.forename: Loredana
authors.initials: L
authors.lastname: Urso
authors.forename: Pierfranco
authors.initials: P
authors.lastname: Conte
authors.forename: Adolfo
authors.initials: A
authors.lastname: Favaretto
mesh_terms: D017209:Apoptosis / Q000187:drug effects; D049109:Cell Proliferation / Q000187:drug effects; D003924:Diabetes Mellitus, Type 2 / Q000150:complications / Q000188:drug therapy*; D006801:Humans; D007093:Imidazoles / Q000008:administration & dosage; D007328:Insulin / Q000235:genetics / Q000378:metabolism; D007334:Insulin-Like Growth Factor I / Q000235:genetics*; D008687:Metformin / Q000008:administration & dosage; D009369:Neoplasms / Q000150:complications / Q000188:drug therapy* / Q000473:pathology; D013450:Sulfones / Q000008:administration & dosage; D013453:Sulfonylurea Compounds / Q000008:administration & dosage*
chemical_list: D007093:Imidazoles; D007328:Insulin; D013450:Sulfones; D013453:Sulfonylurea Compounds; D007334:Insulin-Like Growth Factor I; D008687:Metformin; C404303:DW 2282
keywords: Anticancer agents; Apoptosis; Glibenclamide; Sulfonylurea compounds
references.citation: Metabolism. 2000 Feb;49(2 Suppl 1):14-6
references.pmid: 10693914
references.citation: Metabolism. 2013 Jul;62(7):922-34
references.pmid: 23419783
references.citation: Biochem Pharmacol. 2002 Aug 1;64(3):473-80
references.pmid: 12147299
references.citation: Diabetes Metab Res Rev. 2008 May-Jun;24(4):301-9
references.pmid: 18088078
references.citation: J Clin Oncol. 2012 Jul 20;30(21):2698-700
references.pmid: 22565000
references.citation: Int J Mol Med. 2003 Feb;11(2):261-6
references.pmid: 12525889
references.citation: J Clin Invest. 2005 Aug;115(8):2047-58
references.pmid: 16075046
references.citation: Oncologist. 2012;17(6):813-22
references.pmid: 22643536
references.citation: Chem Biol Interact. 2006 Sep 25;162(3):259-67
references.pmid: 16963009
references.citation: Cancer Res. 1990 Feb 1;50(3):664-8
references.pmid: 2297707
references.citation: J Clin Invest. 2009 Nov;119(11):3246-56
references.pmid: 19805912
references.citation: Anticancer Res. 2002 May-Jun;22(3):1727-30
references.pmid: 12168861
references.citation: Clin Cancer Res. 2003 Nov 15;9(15):5540-9
references.pmid: 14654534
references.citation: Diabetes Care. 2006 Aug;29(8):1990-1
references.pmid: 16873829
references.citation: Nat Rev Cancer. 2008 Dec;8(12):915-28
references.pmid: 19029956
references.citation: Cancer Cell. 2007 Jan;11(1):37-51
references.pmid: 17222789
references.citation: Biochem Pharmacol. 2008 Dec 15;76(12):1705-15
references.pmid: 18840412
references.citation: Metabolism. 2008 Aug;57(8):1038-45
references.pmid: 18640379
references.citation: J Clin Oncol. 2012 Jul 20;30(21):2593-600
references.pmid: 22564993
references.citation: Invest New Drugs. 1995;13(1):63-6
references.pmid: 7499110
references.citation: Diabet Med. 2002 Sep;19(9):752-7
references.pmid: 12207812
references.citation: FEBS Lett. 2012 May 21;586(10):1504-9
references.pmid: 22673517
references.citation: BMC Public Health. 2012 Jul 28;12:567
references.pmid: 22839452
references.citation: J Physiol Pharmacol. 2010 Jun;61(3):347-53
references.pmid: 20610866
references.citation: Biochem Pharmacol. 2001 Dec 1;62(11):1439-47
references.pmid: 11728380
references.citation: J Diabetes Complications. 2010 Sep-Oct;24(5):345-53
references.pmid: 20656522
references.citation: Cancer Cells. 1990 Jun;2(6):163-71
references.pmid: 2201343
references.citation: J Clin Oncol. 2012 Aug 10;30(23):2844-52
references.pmid: 22689798
references.citation: Oncol Rep. 2002 Sep-Oct;9(5):961-4
references.pmid: 12168055
references.citation: Br J Cancer. 2012 Oct 23;107(9):1608-17
references.pmid: 22996614
references.citation: Endocr Pract. 2011 Jul-Aug;17(4):616-28
references.pmid: 21454235
references.citation: Acta Diabetol. 2009 Dec;46(4):279-84
references.pmid: 19082520
references.citation: Endocr Relat Cancer. 2009 Dec;16(4):1103-23
references.pmid: 19620249
references.citation: J Mol Cell Cardiol. 2005 Jul;39(1):7-16
references.pmid: 15978901
references.citation: Anticancer Drugs. 1999 Mar;10(3):303-7
references.pmid: 10327037
references.citation: Diabetol Metab Syndr. 2011 Jul 13;3(1):15
references.pmid: 21752291
references.citation: Cancer Cell. 2006 Sep;10(3):175-6
references.pmid: 16959608
references.citation: Biomed Pharmacother. 2005 May;59(4):163-8
references.pmid: 15862710
references.citation: BMJ. 2005 Jun 4;330(7503):1304-5
references.pmid: 15849206
references.citation: Int J Cancer. 2013 Jan 1;132(1):182-8
references.pmid: 22510866
references.citation: Mol Biol Rep. 2012 May;39(5):5253-67
references.pmid: 22183301
references.citation: Cancer Res. 1991 Dec 1;51(23 Pt 1):6286-91
references.pmid: 1933889
references.citation: Br J Pharmacol. 2001 Feb;132(3):778-84
references.pmid: 11159731
references.citation: J Biol Chem. 2000 Aug 25;275(34):26050-7
references.pmid: 10862612
references.citation: Diabetes Care. 2010 Jun;33(6):1304-8
references.pmid: 20299480
references.citation: J Clin Oncol. 1989 Nov;7(11):1733-40
references.pmid: 2809686
references.citation: Biomed Environ Sci. 2007 Apr;20(2):160-3
references.pmid: 17624192
references.citation: Anticancer Res. 1999 Nov-Dec;19(6B):5087-93
references.pmid: 10697515
references.citation: J Clin Oncol. 2009 Jul 10;27(20):3271-3
references.pmid: 19487373
references.citation: J Clin Oncol. 2009 Jul 10;27(20):3297-302
references.pmid: 19487376
references.citation: Blood. 1997 Oct 15;90(8):2911-5
references.pmid: 9376570
references.citation: Bioorg Med Chem Lett. 2004 Dec 20;14(24):6075-8
references.pmid: 15546733
references.citation: Metabolism. 2012 Feb;61(2):242-9
references.pmid: 21820134
references.citation: JAMA. 2005 Jan 12;293(2):194-202
references.pmid: 15644546
references.citation: Cancer Res. 2002 Sep 1;62(17):4843-8
references.pmid: 12208728
references.citation: J Diabetes Complications. 2000 Jul-Aug;14(4):201-6
references.pmid: 11004429
references.citation: BMC Pharmacol Toxicol. 2013 Jan 11;14:6
references.pmid: 23311706
references.citation: J Med Chem. 1992 Aug 7;35(16):3012-6
references.pmid: 1501228
references.citation: J Clin Oncol. 2013 Mar 1;31(7):973-4
references.pmid: 23358989
references.citation: Diabetes Res Clin Pract. 2010 Dec;90(3):343-51
references.pmid: 20889221
references.citation: J Med Chem. 1990 Sep;33(9):2393-407
references.pmid: 2391684
references.citation: J Clin Oncol. 2012 Aug 10;30(23):2812-4
references.pmid: 22689806
references.citation: Anticancer Res. 1993 Nov-Dec;13(6A):1939-43
references.pmid: 8297099
references.citation: J Urol. 1992 Feb;147(2):500-4
references.pmid: 1732631
references.citation: J Natl Cancer Inst. 1992 Dec 2;84(23):1798-802
references.pmid: 1433369
references.citation: Curr Med Chem. 2008;15(1):61-74
references.pmid: 18220763
references.citation: Gastroenterology. 2000 Feb;118(2):422-30
references.pmid: 10648470
references.citation: ISRN Oncol. 2013;2013:583786
references.pmid: 23476808
references.citation: Diabetes Care. 2012 Jan;35(1):113-8
references.pmid: 22100961
references.citation: Gynecol Oncol. 2007 Feb;104(2):455-60
references.pmid: 17014896
references.citation: J Physiol. 1997 Sep 1;503 ( Pt 2):333-46
references.pmid: 9306276
references.citation: Diabetes Res Clin Pract. 2012 Aug;97(2):331-6
references.pmid: 22386769
references.citation: Cancer Biol Ther. 2008 Dec;7(12):1875-84
references.pmid: 18981733
references.citation: Int J Oncol. 2012 Aug;41(2):465-75
references.pmid: 22613960
references.citation: Invest New Drugs. 1996;14(3):271-80
references.pmid: 8958182
references.citation: J Cell Physiol. 1995 Feb;162(2):163-71
references.pmid: 7822427
references.citation: Chem Biol Interact. 2008 Jun 17;173(3):159-65
references.pmid: 18485337
references.citation: Cancer Detect Prev. 2006;30(4):375-85
references.pmid: 16971052
references.citation: Cancer Lett. 2002 Dec 1;186(1):99-105
references.pmid: 12183081
references.citation: Biochem Pharmacol. 1996 Oct 11;52(7):967-77
references.pmid: 8831715
references.citation: J Membr Biol. 1998 Feb 1;161(3):257-62
references.pmid: 9493131
references.citation: Cancer Epidemiol Biomarkers Prev. 2011 Jan;20(1):101-11
references.pmid: 21119073
references.citation: Diabetologia. 2009 Sep;52(9):1766-77
references.pmid: 19572116
references.citation: Biochem Biophys Res Commun. 2003 Mar 28;303(1):112-9
references.pmid: 12646174
references.citation: FEBS Lett. 2010 May 17;584(10):2063-9
references.pmid: 20178786
references.citation: Pflugers Arch. 1999 Apr;437(5):652-60
references.pmid: 10087141
references.citation: J Exp Ther Oncol. 2004 Jul;4(2):161-6
references.pmid: 15500011